HomeRx, LLC (WellRx, LLC), Wheaton, IL
Is HomeRx, LLC (WellRx, LLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does HomeRx, LLC (WellRx, LLC) hold a Illinois pharmacy license?
The Illinois Department of Financial and Professional Regulation lists license 054020427 for WELLRX, LLC, WHEATON, status CLOSED, as of Nov 13, 2026.
Has HomeRx, LLC (WellRx, LLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Apr 3, 2019) and 1 FMD-145 letter (Apr 3, 2019) for HomeRx, LLC (WellRx, LLC). State board actions: no Illinois Department of Financial and Professional Regulation action on license 054020427 or under this exact name and city was found in the board’s license dataset (actions dated May 23, 1980 to Sep 10, 2026) on Nov 13, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- WellRx, LLC; HomeRx, LLC
- Location
- Wheaton, IL
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 3, 2019
- FDA Data Dashboard inspections
- 1 inspection: 1 OAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 19 observations
- State board records
- License found: 054020427, CLOSED
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as WellRx, LLC (dba HomeRx, LLC), a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Apr 3, 2019 | State referral letter | Referral Letter to the Illinois State Board of Pharmacy Issued 04/03/2019 | FDA copy (archived) |
| Apr 3, 2019 | FMD-145 letter | FMD-145 Letter Issued 04/03/2019 | FDA copy (archived) |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists WellRx LLC, Wheaton, IL (FEI number 3011707930), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 19, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011707930 | 942002 |
Form 483s FDA has published for this site
- Jan 5, 2018: Form 483 to WellRx LLC, published Jan 17, 2024. fda.gov
- Mar 4, 2016: Form 483 to WellRx LLC, published Jan 17, 2024. fda.gov
- Mar 4, 2016: Form 483 to WellRx LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 19 numbered observations in all, across 2 inspections ending Aug 12, 2015 to Nov 13, 2017. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Oct 2, 2017 to Nov 13, 2017: 1 observation
- Firm on the cover
- WellRx. LLC dba HomeRx, LLC, 200 East Willow Avenue, Suite 100, CODE
- FEI number
- 3011707930
- Establishment type on the cover
- WHEATON, IL 60187 Producer of Non-Sterile Drugs
- FDA district office on the cover
- Chicago, IL 60661
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Non-pharmaceutical grade components are used in the formulation of human non-sterile drug products.
Specifically, non-pharmaceutical grade <Redacted B4> water was used to produce the following human non-sterile drug products rather than purified USP grade water. Examples include the following:
1. Rx # <Redacted B6> on 8/21/17 for C-Diphenhydramine 25mg/5ml liquid.
2.Rx # <Redacted B6> on 7/28/17 for C-Diphendydramine 25mg/5ml liquid.
3.Rx# < Redacted B6> on 7/31/17 for C-Scopolamine 0.25mg/0.1ml topical lipoderm.
4. Rx # <Reda cted B6> on 8/17/17 for C-Omeprazole 4mg/ml suspension.
Add Continuation Page
Inspection Jan 19, 2015 to Aug 12, 2015: 18 observations
- Firm on the cover
- Wellcare Rx Investments L LC d ba D enson’s Spe cialty Pha rmacy , 200 E W illow A ve, Wheaton, IL 6 0187-5463
- FEI number
- 3011707930
- Establishment type on the cover
- Producer of Ste rile Dru gs
- FDA district office on the cover
- 550 w. Jackson blvd., s uite 1 500 Chi cago, IL 606 61-471 6
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
During a field examination of drug products at your facility the following was observed:
Specifically,
On 8/ 14/ 15, I observed a vial ofsterile human finished drug product Chlorpromazine HCL 25mg/ml, production lot # 05-070815, prepared on 7/8/15 and expires 10/8/ 15, with what looked like particles floating in the drug product.
Observation 2
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established and written .
Specifically.
During the aseptic preparation ofsterile Atropine 0.01% Ophthalmic Drops, firm lot # 01-082715, performed on 8/27/15 by a technician in the IS0-5laminar air flow hood, I observed the following deficiencies in aseptic technique:
The re is no documented decontamination of the iso 5 laminar air flow hood prior to use. for ex ample, I did not observe the technician wipe down the laminar air flow hood with sterile re dacted b4 before performing aseptic processing of the sterile drug product.
Pac kages containing sterile items necessary for production were not decontaminated / wiped
AMENDMENT1
EIFL0'1I:E(S)SIGMAlU'E
DillE ISSUBl
Pac kages containing sterile items necessary for production were opened outside of the la minar air flow hood exposing sterile contents to the non-sterile room air. For example, I ob served the following. A I observed the technician open three sterile wipes outside of the laminar air flow hood on redacted b4 right side and then place the wipes on the surface of the laminar air
flow hood. ...
Observation 3
Protective apparel is not worn as necessary to protect drug products from contamination.
Specifically,
The apparel worn by personnel while conducting aseptic processing of sterile human drug products does not adequately protect the drug products as follows. For example, on 8/27/15, I observed a technician prepare the sterile drug product, Atropine 0.01% Ophthalmic Drops, firm lot # 01-082715, prepared on 8/27/ 15 and expires on 9/27115 in the ISO-5 Laminar air flow hood in the clean room.
1. The technician had on a non-sterile gown. non-sterile mask, non-sterile bonnet, and non-sterile booties.
2. I observed exposed skin on the face ofthe technician while the drug product was being prepared.
3. The sterile gloves were opened outside ofthe IS0-5 laminar air flow hood and then put them on to prepare the sterile drug product.
AMENDMENT1
Observation 4
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
1. The firm has never performed environmental monitoring during the production of sterile human drug products. For example, on 8/27/15 I observed the production of Atropine 0.01% Ophthalmic Drops, firm lot# 0 l-082715, prepared on 8/27/15 and expires on 9/27/15, in the IS0-5 laminar air flow hood and no environmental monitoring was being performed during production. 1. The firm has never performed environmental monitoring during the production of sterile human drug products. For example, on 8/27/15 I observed the production of Atropine 0.01% Ophthalmic Drops, firm lot# 0 l-082715, prepared on 8/27/15 and expires on 9/27/15, in the IS0-5 laminar air flow hood and no environmental monitoring was being performed during production.
a) The firm has never performed monitoring for viable microbiological contamination in the cleanroom including inside of the laminar air flow hood under static or dynamic conditions. ...
Observation 5
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile do not include validation ofthe sterilization process.
Specifically,
The firm has not validated the aseptic processing of sterile drug products by performing media fil ls. For example, the following drug products have been sterilized by redacted b4 using redacted b4 and no media fills have been performed.
A c yclosporine (a) 1% ophthalmic, firm lot # 13-071615, prepared 7/16/15 and expires 10/16/15.
B V ancomycin 25 mg/ml Ophthalmic, firm lot # 23-081115, prepared 8/11/15 expires 14 days.
C C hlorpromazine HCL 25 mg/ml injection, firm lot #05-070815, prepared 7/8/15 and expires 1 0/8/15.
The firm has not conducted smoke studies in the critical areas to demonstrate uni-directional airf low and sweeping action over and away from the product under dynamic conditions.
The firm failed to validate the red acted b4 used to sterilize some ophthalmic and intra
muscular inj ectab les drug products from redacted b4 drug produ cts. In addition, the firm has not established redacted b 4 bioburden limits in order to determine if it exceeds the redacted b4. ...
Observation 6
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing ofdrug products.
Specifically,
The design ofthe clean room used to produce sterile human drug products is deficient as follows:
1. 1. There is no documentation that the clean room where the IS0-5 laminar air flow hood is located has been qualified by initial studies and classified for air quality and for the particle content in the air when it was built. For example, the following documentation was not available for review during the inspection.
a) Documentation ofan assessment ofthe air quality and the particle content ofthe air under as built static conditions.
b) Documentation ofan assessment ofthe air quality and the particle content ofthe air under dynamic conditions when production ofsterile drug products occurs.
2. There is no ISO classification for the surrounding area outside ofthe IS0-5 laminar air flow hood.
3. There is no pressure differential cascade between the cleanroom and the surrounding area outside ofthe entry door in order to control contamination from entering into the cleanroom where sterile drugs are produced . ...
Observation 7
The batch production and control records are deficient in that they do not include documentation ofthe accomplishment of each significant step in processing.
Specifically,
The prepara tion of sterile drug product does not include documentation of the testing of the redacted b4 used during aseptic redacted b4 of drug products which are required to be sterile. For example, the following drug products are redacted b4 using redacted b4 but the firm did not perform redacted b4 of the redacted b4.The prep aration of sterile drug product does not include documentation of the testing of the redacted b4 used during aseptic redacted b4 of drug products which are required to be sterile. For example, the following drug products are redacted b4 using redacted b4 but the firm did not perform redacted b4 of the redacted b4.
a) Cyclosporine (A) 1 %Ophthalmic, firm lot# 13-071615, prepared 7/16/15 and expires 10/16/15.
b) Vancomycin 25 mg/ml Ophthalmic, firm lot# 23-081115, prepared 8/11115 and expires 14 days.
c) Chlorpromazine HCL 25 mg/ml Injection, firm lot# 05-070815, prepared 7/8115 and expires 10/8/15.
AMENDMENT1
Observation 8
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically,
Sterile human drug products have never been tested for sterility and pyrogens.
1. Chlorpromazine HCL 25 mg/ml Injection, Rx# r edacted b4 redacted b6 produced 7/6/15, lot 06-070815, expires 10/8/15, was not tested for sterility and pyrogens.
2. A tropine 0.01% Ophthalmic Drops, Rx # r edacted b4 b6 produced 7/16/15, lot 03- 0706 15, expires 8/16/15, was not tested for sterility and pyrogens.
3. Edeate Disodium 10% Injection, Rx # <Redaction b4, b6> produced 7/16/15, lot 03-0706 15, expires 8/6/15, was not tested for sterility and pyrogens.
Observation 9
There is no written testing program designed to assess the stability characteristics ofdrug products.
Specifically,
The firm does not have documentation of stability testing data to support the expiration dates assigned to the sterile human drug products. For example, the following sterile human drug products have expiration dates that are based on red acted b4 but the firm has never sent out the finished sterile human drug products to assure the finished drug products meets the specifications for identity, strength, and quality, throughout the assigned expiration date.
AMENDMENT1
M TEIS5UED
C-C hlorpromazine HCL 25 mg/ml Injection, Rx # red acted b4b6 produced 7/8/15, lot 06-070815, expires 10/8/15, was not tested for potency.
Atr opine 0.01% Ophthalmic Drops, Rx # red acted b4b6 produced 9/23/15, lot 11-092 315, expires 11/23/15, was not tested for potency.
Ede ate Disodium 10% injection, Rx redacted b4b6 produced 7/6/15, lot 03-070615, expires 8/6/15.
Edeate Disodium 10% injection, Rx redacted b4b6 produced 7/6/15, lot 03-070615, expires 8/6/15.
Edeate Disodium 10% injection, Rx redacted b4b6 produced 7/6/15, lot 03-070615, expires 8/6/15.
Observation 10
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically,
The following human drug products have never been tested for potency before release.
Chl orpromazine HCL 25 mg/ml injection, Rx # redacted b4b6 produced 7/8/15, lot 06-070815, expires 10/8/15, was not tested for potency.
Chlorpromazine HCL 25 mg/ml injection, Rx # redacted b4b6 produced 7/8/15, lot 06-070815, expires 10/8/15, was not tested for potency.
Chlorpromazine HCL 25 mg/ml injection, Rx # redacted b4b6 produced 7/8/15, lot 06-070815, expires 10/8/15, was not tested for potency.
Atr opine 0.01% Ophthalmic Drops, Rx # redacted b4 b6 produced 9/23/15, lot 11-092315, expires 11/23/15, was not tested for potency.
Atropine 0.01% Ophthalmic Drops, Rx # redacted b4 b6 produced 9/23/15, lot 11-092315, expires 11/23/15, was not tested for potency. Atropine 0.01% Ophthalmic Drops, Rx # redacted b4 b6 produced 9/23/15, lot 11-092315, expires 11/23/15, was not tested for potency. · ...
Observation 11
Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely subjected to microbiological tests before use.Each lot of a component liable to objectionable microbiological contamination is definitely ...
Observation 12
Equipment and utensils are not cleaned and sanitized at appropriate intervals to prevent that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically,
The firm has not qualified and validated the redacted b4, th at i s used to sterilize the redacted b4 that ar e used to produce some sterile drug products. The firm has no evidence that the redacted b4 sterilizes the redacted b4 that are used to produce some sterile drug products.
Observation 13
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Specifically,
The firm does not have current written procedures related to the compounding ofsterile drug products.
A. There is no written procedure that requires a sporicidal agent to be used in the disinfection ofthe laminar air flow hood and the clean room where sterile drugs are produced.
AMENDMENT1
B. There is no written procedure that states when the HEPA filters inside the IS0-5 laminar air flow hood in the cleanroom should be changed and documented.
C t he written procedure in the re dacted b4 manual are not current and have been rev iewed since august 2004. Some of the procedures are not adequate for their intended use an d/or are not followed. Some of these written procedures include the following.
Red acted b4 -Cle an room and hood maintenance. A the procedure does not state to document the cleaning and disin fection of the laminar air flow hood and the cleaning and disinfection of the clean room. ...
Observation 14
Routine calibration, inspection. and checking of electronic equipment is not performed according to a written program designed to assure proper performance.
Specifically, the firm does not have documentation ofcalibration and maintenance ofequipment used in the preparation ofdrug products.
AMENDMENT1
The redacted b4 balance, redacted b4, used to weigh out components (chemical s) which are used to prepare drug products does not have a calibration sticker, there is no documentation of periodic calibration by an outside vendor, and there is no documentation of periodic calibration by employees working at the firm.
There is no documentation of the calibration of the thermometers used in the refrigerator redacted b4, the incubator (brand name redacted b4), and the redacted b4.
There is no documentation of the calibration of the thermometers used in the refrigerator redacted b4, the incubator (brand name redacted b4), and the redacted b4. There is no documentation of the calibration of the thermometers used in the refrigerator redacted b4, the incubator (brand name redacted b4), and the redacted b4. ...
Observation 15
Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.
Specifically,
Components, both active ingredients and non-active ingredients, are not tested before being used to
prepare human sterile drug products. For ex ample, the following components are used to prepare human
sterile drug products.
Hydr oxypprogesterone red acted b4, expire s redacte d b4 prepared on redacted b4 was made with the following components..
A active i ngredient hydroxyprogesterone redacted b4.
Red acted b4 , prepared on redacted b4, expires redacted b4, was made with the following components. A a ctive i ngredient papverine redacted b4
AMENDMENT1
Observation 16
Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable size to facilitate cleaning, maintenance, and proper operations.
Specifically,
On 8/12/15, I observed the following conditions in the cleanroom at the firm where sterile drug products are produced.
I. 1. Shelves and carts used in the cleanroom are made of material that cannot be easily decontaminated.
a)
b) A metal shelfcontaining supplies in plastic bins on the opposite side ofthe IS0-5 laminar air flow hood. Some ofthe supplies included a container ofpH paper, and a box ofsterile needles. c) Several plastic bins with sterile supplies such as gloves, bottles, and caps. d) Two wooden carts containing plastic bins. The carts were stored underneath the counter top next to the IS0-51aminar air flow hood. Each ofthe bins had supplies such sterile gloves, sterile syringes, sterile saline or water for production. e) A counter top next to the iso 5 laminar air flow hoodd containing a small incubator, a
redacted b4, and a bottle of redacted b4
2. Equipment was stored in the clean room that was not used to prepare sterile drug products. ...
Observation 17
Time limits are not established when appropriate for the completion ofeach production phase to assure the quality ofthe drug product.
Specifically,
Time limitations have not been established for some redacted b4 used to prepare sterile drug products prepared by the firm. For example, the following redacted b4 was used to prepare drug products and time limitations have not been established to determine how long it can be used.Time limitations have not been established for some redacte d b4 used to prepare sterile drug products prepar ed by the firm. For example, the following redacted b4 was used to prepare dr ug products and time limitations have not been established to determine how long it can be used.
Hydtoxyprogesterone reda
cted b4, was used to make a redacted b4, prepar
ed on redacted b4, and expires redacted b4. The firm does not have data to support that the redacted b4 can be held for redacted b4 and is stable for this time period. Redacted b4, sterile drug products that are injected intramuscularly.
A Hydroxyprogeste
rone redacted b4, was used to make redacted b4, prepared on redacted b4, expiration redacted b4. ...
Observation 18
Specifically, the firm has no data to demonstrate the effectiveness of the sporicide, redacted b4 as a sporicidal agent. It is used in the redacted b4
Specifically, the firm has no data to demonstrate the effectiveness of the sporicide, redacted b4 as a sporicidal agent. It is used in the redacted b4
Linked 483s whose text is not shown
- Mar 4, 2016: FDA document 95420: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
The Illinois Department of Financial and Professional Regulation file dated Nov 13, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| 054020427 | LICENSED PHARMACY | WELLRX, LLC | WHEATON | CLOSED |
What this covers: Discipline IDFPR publishes with each license in the dataset (case number, action, start date and the department’s one-line reason), worded as the department gives it. The dataset marks 931 of these licenses as ever disciplined; some of them carry no action in the dataset. Actions in the data are dated May 23, 1980 to Sep 10, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Illinois Department of Financial and Professional Regulation license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.